Close
Prognostic value of Interferon Gamma Release Assays in predicting active tuberculosis among individuals with, or at risk of, latent tuberculosis infection
What is the efficacy of Interferon Gamma Release Assays in predicting active tuberculosis among individuals with, or at risk of, latent tuberculosis infection?
The objective of this study is to assess the efficacy of the two current TB (tuberculosis) blood tests (Interferon Gamma Release Assays (IGRA)) compared with the standard skin test (Mantoux Tuberculin Skin Test (TST)), for predicting active tuberculosis among those at increased risk of TB. Those at increased risk are defined as either newly arrived immigrants or people who have been in contact with TB cases. The study will also provide information on the cost effectiveness of different testing strategies, such as the two step testing approach recommended by NICE. The study is to be funded by the NIHR Health Technology Assessment programme. 10,000 participants will be recruited from 40 hospitals and a network of GP surgeries in London. All participants will have the skin test and blood taken for both assays. Disease status of participants will then be followed up for an average of 24 months using the national register of clinical reports, a phone call and the national microbiological database. The risk of developing active disease is highest in the first two years after exposure. A sub group of patients, selected as a random 25% of participants, will have a repeat IGRA test shortly after the first test to investigate whether the skin test affects the result of the blood test.
Further details, please contact
Dr Jo Southern
Public Health England (PHE)
Centre for Infections
Health Protection Agency
61 Colindale Avenue
London
NW9 5EQ
UNITED KINGDOM
Tel: 0208 327 6084
jo.southern@phe.gov.uk
